Abstract |
Metoclopramide (Paspertin) was infused intravenously in the high doses of 1.75, 3.5, 7.0, and 14 mg/kg body wt. per treatment cycle as antiemetic therapy for cisplatin-induced emesis (363 cycles, 25-120 mg/m2). The antiemetic potency of metoclopramide increased in a log linear manner, giving from 40% to 95% protection against emesis. Gastrointestinal motility showed a similar increase, i.e. diarrhoea. In contrast, the extrapyramidal reactions, namely akathisia, rigidity and acute dystonia, did not show a dose-dependent increase in frequency and remained constant over the dose range of 3.5-14 mg/kg per cycle. The results suggest increasing benefit of metoclopramide treatment with increasing doses of the drug.
|
Authors | R Saller, D Hellenbrecht, A Hellstern, H Hess |
Journal | European journal of clinical pharmacology
(Eur J Clin Pharmacol)
Vol. 29
Issue 3
Pg. 311-2
( 1985)
ISSN: 0031-6970 [Print] Germany |
PMID | 4076327
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Basal Ganglia Diseases
(chemically induced)
- Cisplatin
(adverse effects)
- Dose-Response Relationship, Drug
- Hemodynamics
(drug effects)
- Humans
- Metoclopramide
(administration & dosage, adverse effects, therapeutic use)
- Risk
- Vomiting
(chemically induced, drug therapy)
|